General Information of Drug Transporter (DT)
DT ID	DTD0005 Transporter Info
Gene Name	SLC22A7
Protein Name	Organic anion transporter 2
Gene ID	10864
UniProt ID	Q9Y694
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs2270860
Site of GPD	chr6:43302413 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.4631/2319 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the increased likelihood of drug toxicity in patients (compare with genotypes CC + CT)		[ 1]
Capecitabine	N.A.	Drug Toxicity	Genotype TT is associated with increased likelihood of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 1]
Capecitabine	N.A.	Neoplasms	Genotype TT is associated with increased likelihood of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Drug Toxicity	Patients with the CC genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.		[ 1]
Capecitabine	N.A.	Neoplasms	Patients with the CC genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Drug Toxicity	Patients with the CT genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.		[ 1]
Capecitabine	N.A.	Neoplasms	Patients with the CT genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.		[ 1]
Genetic Polymorphism	rs4149178
Site of GPD	chr6:43304450 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.1897/950 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the decreased likelihood of diarrhea in patients (compare with genotype AA)		[ 1]
Capecitabine	N.A.	Diarrhea	Genotypes AG + GG are associated with decreased likelihood of Diarrhea when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype AA.		[ 1]
Capecitabine	N.A.	Neoplasms	Genotypes AG + GG are associated with decreased likelihood of Diarrhea when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype AA.		[ 1]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Daunorubicin	N.A.	Cardiotoxicity	Allele G is associated with decreased likelihood of cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele A.		[ 2]
Doxorubicin	N.A.	Cardiotoxicity	Allele G is associated with decreased likelihood of cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele A.		[ 2]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Diarrhea	Patients with the AA genotype and Cancer who are treated with Capecitabine may have an increased risk of Diarrhea as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine		[ 1]
Capecitabine	N.A.	Neoplasms	Patients with the AA genotype and Cancer who are treated with Capecitabine may have an increased risk of Diarrhea as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Diarrhea	Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine		[ 1]
Capecitabine	N.A.	Neoplasms	Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Diarrhea	Patients with the GG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine		[ 1]
Capecitabine	N.A.	Neoplasms	Patients with the GG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine		[ 1]
References
1	Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacol Res. 2017 Jun;120:133-137.
2	Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015;16(10):1065-76.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.